Veracyte reported Q2 sales of $114.43 million, beating estimates by $14.3 million. Testing revenue rose 31% to $107 million, driven by Decipher Prostate and Afirma tests. Guidance for full-year revenue raised to $432 million-$438 million, indicating strong growth. Record volumes for prostate and Afirma tests suggest robust demand and market confidence. Analysts maintain positive ratings, highlighting Veracyte's growth potential amid a competitive landscape.
- Veracyte's shares rose by 6% post-earnings, with an earnings surprise average of 59.65%. - Expected 11.9% earnings growth in 2024, with revenues expected between $402-410 million. - Continued market share growth with Afirma solution and new acquisition of C2i Genomics. - Strong cash position, no current debt, and rising current ratio to 5.00. - Zacks consensus estimate for 2025 moved up from 1 cent to 7 cents. Price Impact Rating: bullish Impact Horizon Rating: long-term Type: Research Analysis
